Savvy Stock Picks

Superconductor Technologies, Inc. (Public, NASDAQ:SCON) increased 2.68%, to close at $1.53 and its overall traded volume was 120,296.00 shares during the last session against its average volume of 76,150.00. SCON opened the day at $1.47, it made an intraday low of $1.46 and an intraday high of $1.54. The stock has a 52 week low of $1.30 and 52 week high of $3.85. SCON’s market capitalization is 41.64M and it has 27.22M outstanding shares.

About Superconductor Technologies, Inc. (Public, NASDAQ:SCON)

Superconductor Technologies Inc. is engaged in the research, development, manufacture and marketing of infrastructure products for wireless voice and data applications. The Company’s product offerings include SuperLink, AmpLink and SuperPlex. The Company sells most of its commercial products to a small number of wireless carriers in the United States, including Alltel, AT&T, Sprint Nextel, T-Mobile and Verizon Wireless. As of December 31, 2009, the Company focused on applications in areas, such as wireless networks, superconducting power applications and government products.

Genomic Health, Inc. (Public, NASDAQ:GHDX) decreased -1.24%, to close at $22.36 and its overall traded volume was 120,199.00 shares during the last session against its average volume of 167,479.00. GHDX opened the day at $22.63, it made an intraday low of $21.94 and an intraday high of $22.90. The stock has a 52 week low of $11.94 and 52 week high of $23.72. GHDX’s market capitalization is 645.25M and it has 28.86M outstanding shares.

About Genomic Health, Inc. (Public, NASDAQ:GHDX)

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer. The Company’s Oncotype DX platform utilizes quantitative genomic analysis in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. Its Oncotype DX breast cancer test has extensive clinical evidence validating its ability to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It offers the Oncotype DX breast cancer test as a clinical service, where it analyzes the expression levels of 21 genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score. The test also provides measurements of quantitative gene expression for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), genes.

Sykes Enterprises, Incorporated (Public, NASDAQ:SYKE) decreased -1.96%, to close at $20.55 and its overall traded volume was 119,834.00 shares during the last session against its average volume of 218,970.00. SYKE opened the day at $21.00, it made an intraday low of $20.41 and an intraday high of $21.00. The stock has a 52 week low of $10.85 and 52 week high of $26.45. SYKE’s market capitalization is 962.78M and it has 46.85M outstanding shares.

About Sykes Enterprises, Incorporated (Public, NASDAQ:SYKE)

Sykes Enterprises, Incorporated (SYKES) is engaged in providing outsourced customer contact management solutions and services in the business process outsourcing (BPO) arena. The Company provides a range of customer contact management solutions to a range of clients including Fortune 1000 companies, medium sized businesses, and public institutions around the world, primarily in the communications, technology/consumer, financial services, healthcare, and transportation and leisure industries. It serves its clients through two geographic operating regions: the Americas (United States, Canada, Latin America and Asia Pacific) and Europe, Middle East and Africa (EMEA). Its Americas and EMEA groups primarily provide customer contact management services (with an emphasis on inbound technical support and customer service), which includes customer assistance, healthcare and roadside assistance, technical support and product sales to its client’s customers.

BioDelivery Sciences International, Inc. (Public, NASDAQ:BDSI) increased 4.21%, to close at $2.97 and its overall traded volume was 119,370.00 shares during the last session against its average volume of 123,715.00. BDSI opened the day at $2.85, it made an intraday low of $2.85 and an intraday high of $2.98. The stock has a 52 week low of $2.12 and 52 week high of $4.44. BDSI’s market capitalization is 71.35M and it has 24.02M outstanding shares.

About BioDelivery Sciences International, Inc. (Public, NASDAQ:BDSI)

BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company utilizing licensed and owned drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new formulations of therapeutics. The drug delivery technologies include the BioErodible MucoAdhesive (BEMA) technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek), and the Bioral cochleate drug delivery technology, designed for the oral delivery of a range of products otherwise administered intravenously. The Company’s United States Food and Drug Administration (FDA) product, ONSOLIS (fentanyl buccal soluble film), as well as the developmental stage products, utilizes the BEMA technology. The Bioral formulation is an encochleated version of Amphotericin B, a treatment for fungal infections.

ABIOMED, Inc. (Public, NASDAQ:ABMD) increased 0.21%, to close at $9.77 and its overall traded volume was 119,325.00 shares during the last session against its average volume of 329,118.00. ABMD opened the day at $9.80, it made an intraday low of $9.71 and an intraday high of $9.80. The stock has a 52 week low of $7.80 and 52 week high of $12.25. ABMD’s market capitalization is 369.73M and it has 37.84M outstanding shares.

About ABIOMED, Inc. (Public, NASDAQ:ABMD)

Abiomed, Inc. is a provider of medical devices in circulatory support and offers a continuum of care in heart recovery to acute heart failure patients. The products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and/or in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophelactically during high risk angioplasty procedures or who are in pre- shock, shock or profound cardiogenic shock.